Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtech Start-Up Financing Strategies: Where’s The Money?

This article was originally published in Start Up

Executive Summary

Despite the dire headlines, VCs are still investing in medtech start-ups, although the deals are becoming fewer and later stage. Start-ups looking for funding have to be more creative and look beyond traditional sources of funding, according to a discussion by six European venture capitalists speaking at the IN3 meeting in Dublin in April 2013.


Related Content

EIF Putting Euros To Work In European VCs, Angels
Overcoming The Bias Against Medtech Entrepreneurship In Europe: An Interview With Martin Rothman
Device Investors Showing Some Spine
Medtech Investing In Europe: Nowhere To Go But Up
Symetis: Well-Positioned Next-Generation TAVI Player
MD Start – Can Medtech Incubators Work In Europe?
Medtech in Ireland -- Turning Green into Gold
Avedro Financing Highlights New Ophthalmology Market
Stentys' IPO: European Public Markets Opening For Device Companies?
In Glaucoma, Devices Go Eye-to-Eye with Drugs


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts